FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
In this Phase I/II clinical trial, the investigators seek to pilot the addition of
hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer,
FOLFOX/bevacizumab. In toxicity terms, the investigators previous studies lead them to
believe that a full dose (800mg) of HCQ will be well-tolerated in this setting. By starting
at 600 mg, the investigators will ensure that the full dose is approached with an eye to
safety, and if needed, the investigators will use the lower dose. Both doses achieve
autophagy inhibition in our current studies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania